In this article, we will discuss about TRODELVY (Dosage Overview). So, let’s get started.
TRODELVY is indicated for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Important Use Information
Do not substitute TRODELVY for or use with other drugs containing irinotecan or its active metabolite SN-38.
Recommended Dose and Schedule
The recommended dose of TRODELVY is 10 mg/kg administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles. Continue treatment until disease progression or unacceptable toxicity. Do not administer TRODELVY at doses greater than 10 mg/kg.
Administer TRODELVY as an intravenous infusion only. Do not administer as an intravenous push or bolus.
First infusion: Administer infusion over 3 hours. Observe patients during the infusion and for at least 30 minutes
following the initial dose, for signs or symptoms of infusion-related reactions.
Subsequent infusions: Administer infusion over 1 to 2 hours if prior infusions were tolerated. Observe patients during the
infusion and for at least 30 minutes after infusion.